We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Niox Group Plc | LSE:NIOX | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 1.40 | 2.06% | 69.40 | 160,758 | 16:35:17 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 67.00 | 69.80 | 69.80 | 69.80 | 69.80 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 36.8M | 9.5M | 0.0225 | 31.02 | 287.04M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:17 | UT | 22,429 | 69.40 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 01/10/2024 | 07:00 | UK RNS | Niox Group PLC Total Voting Rights Update |
| 30/9/2024 | 13:00 | UK RNS | Niox Group PLC Block Listing Interim Review |
| 24/9/2024 | 21:29 | ALNC |  EARNINGS: HSS Hire swings to loss, while Niox profit increases |
| 24/9/2024 | 07:01 | UK RNS | Niox Group PLC Proposed Tender Offer & Notice of General Meeting |
| 24/9/2024 | 07:00 | UK RNS | Niox Group PLC INTERIM RESULTS FOR SIX MONTHS ENDED 30 JUNE 2024 |
| 18/7/2024 | 15:40 | UK RNS | Niox Group PLC Holding(s) in Company |
| 17/7/2024 | 18:53 | ALNC | TRADING UPDATES: NIOX revenue up; Panthera begins Bido drilling |
| 17/7/2024 | 07:00 | UK RNS | Niox Group PLC Trading Update |
| 01/7/2024 | 07:00 | UK RNS | Niox Group PLC Directorate Change |
| 25/6/2024 | 17:52 | UK RNS | Niox Group PLC PDMR / PCA Shareholding |
Niox (NIOX) Share Charts1 Year Niox Chart |
|
1 Month Niox Chart |
Intraday Niox Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 08/10/2024 | 16:06 | NIOX GROUP - expertise in asthma diagnosis and management | 226 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-10-11 15:35:17 | 69.40 | 22,429 | 15,565.73 | UT |
| 2024-10-11 15:29:45 | 68.44 | 955 | 653.60 | O |
| 2024-10-11 15:23:46 | 68.44 | 7,100 | 4,859.24 | O |
| 2024-10-11 15:17:59 | 68.44 | 12,000 | 8,212.80 | O |
| 2024-10-11 15:17:04 | 68.40 | 29,239 | 19,999.48 | O |
| Top Posts |
|---|
Posted at 12/10/2024 09:20 by Niox Daily Update Niox Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NIOX. The last closing price for Niox was 68p.Niox currently has 422,120,630 shares in issue. The market capitalisation of Niox is £294,640,200. Niox has a price to earnings ratio (PE ratio) of 31.02. This morning NIOX shares opened at 69.80p |
Posted at 08/10/2024 16:06 by earwacks O good Jimmy. I see the cut off date is actually oct 15th. I think most people have the same plan to reinvest at a lower price. Be interesting to see how that works out. I will probably keep the cash for a bit to see how the share price settles. Don’t think It needs to be rushed reinvesting as the home test is still a way off production, but a possible takeout is always on the cards. In the meantime we keep getting a hefty wedge of the increasing cash generation |
Posted at 21/7/2024 19:37 by badday Gets a mention on the Paul Scott podcast ( always worth a listen)Interesting that he says Christopher Mills due to do Paul Hills (Vox Markets) interview next week. Christopher Mills was thinking it was fully valued for now, but growing into that value. Might have something to say Anyway Paul Scott comments below: “Another interesting company that I've gone green on, which might surprise you, because it's not my usual sort of value share, is a thing called NIOX, N-I-O-X. That put a trading update out. I had another refresh of the figures. It's quite pricey, but it does something to do with asthma products. And look at the shareholder list on that. You've got Harwood, you've got AstraZeneca, and you've got somebody else who owned about a third of the shares, who were all big name major investors. So the way I look at it is, they've done the due diligence for us, haven't they? And they obviously think it's good, although... Oh, that was it, Rathbones had bought some shares from the other two big shareholders. Richard Griffith, I think, was the other one who's got a big position there. He doesn't get everything right, nobody does, but he's certainly a smart cookie. Anyway, so Niox, I think, is worth you having a look at.” From Small Caps Podcast with Paul Scott: Episode 29 (20 July 2024) - UK Small/Mid Caps with Paul Scott, 20 Jul 2024 This material may be protected by copyright. |
Posted at 16/7/2024 15:13 by earwacks Just been reading a rather bizarre report on the med tech sector. Firstly there are some glaring omissions namely COG and Vrci,and having declared the whole sector has underperformed the market while Niox is ‘a very strong hold’ having declared they are over cautious on their forecasts but is up with events! They also reckon there is plenty of room in the cash pile to pay another special dividend of 2.5p. They also have Thermo Fisher (common interest with Vrci) pushing their product in Spain and two bigger concerns doing the same in USA. I still think it was significant that the CFO moved shares into his SIPP in April and transferred shares into his wife's ISA @68p.Whether it is or not should become apparent in the imminent update. Then there is the by no means not insignificant 600 million tax credit which Chris Mills quite reasonably identified as an asset. Its possible there may have been a blip somewhere but their conservative forecast was ‘inline’ rather than last years ‘ahead’. None the less they still only have a fraction of the market they are in and virtually unopposed. Gl all |
Posted at 14/6/2024 12:11 by saadia110 Think he is still selling. 1.3M buy just gone in at 68.3p. Even with a big seller there are an almost equal number of buyers so don't expect the share price to dip too much. |
Posted at 22/5/2024 07:13 by badday Short and sweet, and bowling along nicely.Trading Update We are pleased to report that our business has continued to perform strongly in the year to date, in line with management expectations. In January 2024, NIOX settled returns claims amounting to £0.4m in relation to the discontinued business. The unaudited cash balance as at 30 April 2024 was £23.7m (31 December 2023: £19.9m), with no bank borrowings. NIOX expects to give a trading update in relation to the six months ended 30 June 2024 around the middle of July. |
Posted at 02/5/2024 08:37 by earwacks Have been delving further back into Circassia history. This is looking one of the more bizar Aim stories and there have been many. Apparently cir floated at £3.60 back in the day. Something to do with cat allergies! Thats me. My partner has two. Nightmare, but we also have a dog to defend me. Anyway obviously cir was a complete crackpot company under old management and got badly tangled up with Astra. Guess who came out on top? However Ian Johnson, like Chris Mills I clocked when he took Bioquel on a very successful journey about the same time as Cir were in their early days. Quite how Johnson came to Cir to take the reigns I’m not sure, but he certainly worked his magic on it. Just watched an old video of Andy Brough (schroders)talking about how he always gets interested when he hears Chris Mills is involved on the board of a biotech. I remember Mills saying all the serious money had been made on Niox when it was 50p, and it couldnt make 60p under its own steam, inferring a buyout I guess. It went on up to 75p under its own steam with a little help from a special dividend payout. Subsequently it fell back a bit. People keep saying its expensive, but I feel that is only when looking at current valuations. I remember valuations in companies being a lot higher than this pre Covid. Recently Niox have offered employees a 3 year savings plan for shares at 51p which I find curious. In light of recent developments with COPD, the upgrading of a new FeNo diagnostic instrument (the old one having a 5 year max shelf life limit) and the development of a home diagnostic kit, I find myself thinking these shares are bloody cheap still. Incidentally Mills is on the board of EKF (I have a smaller portion) and has made two £100,000 this year, one very recently when they announced results which as expected were not great. But they make enzymes! Or are trying to. He also has connections with Vrci and Renx, (kidney diagnostics) both of which have come off the boil a bit. Tempted for a small position, but they would definitely stretch my risk appetite. And why not just stick with what you know, Niox! |
Posted at 30/4/2024 08:58 by earwacks Edward. Sounds fantastic. If successful that doubly underestimates the potential for Niox. Even Chris Mills seems to have not understood Niox. I think it was last year he commented Niox couldn’t reach 60p under its own steam! It smashed through that in a couple of months. He has been very bullish and it was him that flagged up the humongous tax credit. Personally I thought a target by one broker of £1.20 under its own steam was not pie in the sky considering 95 percent of their market is up for grabs. Requires replacing every 5 years depending on usage. Mills did point out this is a razor blade stock. Sounds like they have also reinvented another Gillette. dividend declared for next months and possibly another special on the cards. Have to admit this is now about a third of my portfolio and am not interested in top slicing. I have a few duffers in my portfolio but would rather kick them out frankly. My best pick since Arm holdings. Gl |
Posted at 27/4/2024 15:19 by earwacks Astra dissolved their partnership with Circassia over Tudorza and Duklar inhaler for COPD.Astra retained commercial rights in consideration of 150 million dollar debt and retained 18 percent of Circassia, now Niox. Astra have since offloaded this product. Not sure how successful it has been. Probably nothing like the FeNo tester. What Niox have is the development of the best Asthma diagnostic device and 600 million tax credit for the Circassia debacle. Meaning they will never pay tax on their very cash generative device. The tax credit is also transferable which makes it an added asset to their £270 million market cap. The directors are probably nearing retirement. They have built a highly profitable business from the wreckage of Circassia, making it a market leader in its field, but still only tapping 5 percent of possible world market. Added to that they are developing a domestic kit, which if successful will probably appeal to a us pharma giant, not necessarily just Astra, who as you say may not be interested as it is Gsk that have recently purchased a company that have developed an asthma drug. Potential for Niox is pretty big and are at an interesting stage where they might need some serious gearing up to reach potential global markets, whilst having converted themselves into a growing cash machine. Although expensive on last years results I don’t think forecasters have quite got their head around the potential of Niox yet |
Posted at 23/2/2024 18:18 by earwacks I think it’s held up well considering The uk is the worst performing market in the world and many British companies make most of their money in global business.This is a recent high for NIOX. It is similar to share price movement last year between update and actual results. News on dividend and cash position should help re establish the share price Then of course there is the expectant takeover by AZN Why else would they hold 16 percent of the. Company? Gl all |
Posted at 19/12/2023 06:03 by earwacks Paul Hill catches up with GuyHarwood on his various funds. Brief mention of Niox and the home kit. Suggests they would need a partner to get this to retail. Well we know for a fact they have set aside money ( 2 million) for the home kit, and aside from that it sounds like the accelerating cash generation is set to continue with solid dividend cover. I listen with great interest to his other life science projects which all seem to need funding in some way at a very difficult time.They have no tax to pay for yonks due to the unbelievable tax loss carry over of 600 million! So what are they going to do with the ever expanding cash pile? Richard Griffiths still reducing gradually and still the largest holder. Clearly someone is happy to take them off his hands but maybe what has halted the rise of the share price for now. With the share price seemingly consolidating around this level looks a good opportunity to add. As keen as I am to diversify, I just can’t see a better case for investing than here. I particularly like that they don’t really push this stock. They don’t need to, the numbers do the talking! Still up for a buy out but the sales will quickly catch up the premium rating PE of 22, not actually that expensive for a company with high teens revenue growth and great margins with recurring refill product. Gl |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
